ClinicalTrials.gg
RecruitingNCT06297239GAELpaUpdated Mar 7, 2024

Argentine Registry of Lp(a)

An observational study in Lp(A), Hypercholesterolemia and Cardiovascular Diseases, sponsored by School of Medicine. National University of Cuyo. Recruiting at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by School of Medicine. National University of Cuyo · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Hypercholesterolemia with a site in Argentina — 3 open to participants now, 7 under way, 5 of them phase 3. Hypercholesterolemia · Argentina.

Started
2024
with 3 others
Observational
2 of 19
1 open now
Registered
15th of 19
by date
Lead sponsor
1 of 19
School of Medicine. National University of Cuyo

Among the 19 studies in Hypercholesterolemia with a site in Argentina, this one is one of 4 that started in 2024, is one of 2 observational ones, and was the 15th registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 19 studies in Hypercholesterolemia with a site in Argentina are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hypercholesterolemia with a site in Argentina, or all of them as a file.
02

Study summary

The Argentine Registry on Lipoprotein(a) (LP(a)), orchestrated by the Argentine Group for LP(a) Study, stands as a pioneering and extensive prospective initiative. This registry systematically collects geolocation data, including patient postal codes, demographic information, and a multifaceted array of health parameters to unravel the intricate associations surrounding LP(a) levels.

The dataset encompasses diverse patient characteristics, ranging from standard metrics like blood pressure, weight, and race to broader factors such as diabetes, smoking habits, menopausal status, and hypothyroidism. This holistic approach enables a nuanced exploration of the interplay between LP(a) levels and various risk factors, providing invaluable insights for both clinical and public health considerations.

One distinctive feature of this registry lies in its focus on medication history, shedding light on the impact of routine pharmaceutical interventions on LP(a) profiles. Additionally, it delves into the intricate web of inflammatory diseases, recognizing their potential role in LP(a) modulation.

Genetic predispositions are meticulously examined, with a specific emphasis on identifying homozygous and heterozygous variants associated with hypercholesterolemia. This genetic dimension adds a layer of complexity to the understanding of LP(a) dynamics, contributing significantly to the ongoing discourse on cardiovascular risk.

The prospective nature of this registry allows for dynamic analyses, fostering a continuous exploration of emerging patterns and trends. By amalgamating geographical, clinical, and genetic data, the Argentine LP(a) Registry emerges as a comprehensive platform poised to unlock novel facets of LP(a) biology and its implications for cardiovascular health. As the dataset matures, it holds the promise of guiding personalized interventions and refining risk stratification strategies, thereby advancing the landscape of preventive cardiovascular care.

03

Conditions studied

  • Lp(A)
  • Hypercholesterolemia
  • Cardiovascular Diseases
  • Diabete Type 2
  • Hypertension

Keywords

  • LP(a)
  • Cardiovascular risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients residing in Argentina

Eligibility criteria

Inclusion Criteria: Adult patients with validated Lp(a) values -

Exclusion Criteria: Associated pathologies that can increase the Lp(a) value in a non-specific manner

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. prevalence of high level of Lp(a)

    prevalence of high level of Lp(a)

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Universidad Nacional de Cuyo
    Mendoza, 5500, Argentina
    Recruiting
    • Nicolás F Renna, PhD MD FESC · Contactnicolasfede@gmail.com · +5492615714415
    • Pablo Corral, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2026, 24 months after the start.

Of 51 observational studies under Hypercholesterolemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 59. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 7, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Feb 1, 2026
CompletionEst.
Feb 1, 2026
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06297239
Lead sponsor
School of Medicine. National University of Cuyo
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Feb 1, 2024
Primary completion
Feb 1, 2026 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Mar 7, 2024

Study contacts

Nicolás F Renna, MD PhD FESC
Contact
nicolasfede@gmail.com
+5492615714415
Pablo Corral, MD
Contact
drpablocorral@gmail.com
Pablo Corral, MD
study chair · FASTA University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion